clinical trial · NCT07168161
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
Staidson (Beijing) Biopharmaceuticals Co., Ltd·phase3·recruiting·n = 300
ANCA Associated Vasculitis (AAV)BDB-001 injectionCyclophosphamideRituximabAzathioprinePrednisone
brief summary
The primary aim is to study the efficacy of treatment with BDB-001 Injection to induce remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab
started
Nov 10, 2025
primary completion
Apr 16, 2027
completion
Feb 29, 2028
last updated
Apr 23, 2026
official title
A Multicenter, Randomized, Double-Blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of BDB-001 Injection in Patients With ANCA-Associated Vasculitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol